TABLE 4

Summary of clinical botanical-drug interaction potential of in vitro natural inhibitors

Compounds with Moderate to High Interaction Risk (Need Clinical Interaction Study)
Δ9-Tetrahydrocannabinol
Cannabidiola
Cannabinol
Naringenina
Quercetin
Luteolin
Cryptotanshinone
Oleanolic acida
Ursolic acida
Asiatic acida
Gambogic acidb
Glycyrrhetic acid
Studied In Vitro but Lacking Pharmacokinetic Data for Interpretation (Need Phase 0 Study)
Galangin
MorinDihydrotanshinone
NeobavaisoflavoneMiltirone
CorylifolininMaslinic acid
CoryfolinHederagenin
CorylinCorosolic acid
BavachininPomolic acid
WogoninPolygalacic acid
NevadensinBetulinic acid
HerbacetinBetulin
Dammarenediol IIBetulinic acid-28-methyl ester
20S-O-β-(d-glucosyl)-dammarenediol IIAcetylbutulinic acid
PanaxadiolDehydropachymic acid
PanaxatriolPolyporenic acid C
Magnololβ-Lapachone
Schisandrin BGoldenseal (mixture)

  • ↵a High interaction risk as evidenced by a [I]/(Ki or IC50) value >1.

  • ↵b Regulates CES1 expression.